Discover
KNSA
Kiniksa Pharmaceuticals International, plc
62.88
2 x 45.37
2 x 80.24
bid
ask
-
1.07
1.67%
2 @ 04:00 PM
59.20 -3.68 (5.86%)
| Ytd | 52.45% | |
| 1y | 130.86% |
62.60
day range
64.09
26.27
52 week range
64.81
| Open | 63.64 | Prev Close | 63.95 | Low | 62.60 | High | 64.09 | Mkt Cap | 4.84B |
| Vol | 657.01K | Avg Vol | 804.98K | EPS | 0.91 | P/E | 69.10 | Forward P/E | 35.78 |
| Beta | 0.12 | Short Ratio | 5.52 | Inst. Own | 102.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 53.39 | 200-d Avg | 44.93 | 1yr Est | 65.13 |
KNSA News
zacks.com
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for
zacks.com
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gain
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-averag
benzinga.com
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf
zacks.com
Grab These 4 Stocks With Solid Net Profit Margins to Maximize Returns
Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and risin
zacks.com
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipelin